Literature DB >> 21292307

Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.

Viju Ananthanarayanan1, Ryan J Deaton, Anup Amatya, Virgilia Macias, Ed Luther, Andre Kajdacsy-Balla, Peter H Gann.   

Abstract

Previous investigations have linked decreased nuclear expression of the cell cycle inhibitor p27 with poor outcome in prostate cancer. However, these reports are inconsistent regarding the magnitude of that association and its independence from other predictors. Moreover, cytoplasmic translocation of p27 has been proposed as a negative prognostic sign. Given the cost and accuracy limitations of manual scoring, particularly of tissue microarrays, we determined if laser-based fluorescence microscopy could provide automated analysis of p27 in both nuclear and cytoplasmic locations and, thus, clarify its significance as a prognostic biomarker. We constructed tissue microarrays covering 202 recurrent cases (rising prostate-specific antigen) and 202 matched controls without recurrence. Quadruplicate tumor samples encompassed 5 slides and 1616 cancer histospots. Cases and controls matched on age, Gleason grade, stage, and hospital. We immunolabeled epithelial cytoplasm with Alexafluor 647, p27 with Alexafluor 488, and nuclei with 4c6-diamidino-2-phenylindole·2HCl. Slides were scanned on an iCys laser scanning cytometer (CompuCyte Corp, Cambridge, MA). Nuclear crowding required a stereological approach--random arrays of circles (phantoms) were layered on images and the content of each phantom was analyzed in scatter plots. Both nuclear and cytoplasmic p27 were significantly lower in cases versus controls (P = .014 and P = .004, respectively). Regression models controlling for matching variables plus prostate-specific antigen showed strong linear trends for increased risk of recurrence with lower p27 in both nucleus and cytoplasm (highest versus lowest quartile; odds ratio, 0.35; P = .006). Manual scoring identified an inverse association between p27 expression and tumor grade but no independent association with recurrence. In conclusion, we developed an automated method for subcellular scoring of p27 without the need to segment individual cells. Our method identified a strong relationship, independent of tumor grade, stage, and prostate-specific antigen, between p27 expression--regardless of subcellular location--and prostate cancer recurrence. This relationship was not observed with manual scoring.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21292307      PMCID: PMC3095701          DOI: 10.1016/j.humpath.2010.10.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  29 in total

1.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

2.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.

Authors:  P L Porter; K E Malone; P J Heagerty; G M Alexander; L A Gatti; E J Firpo; J R Daling; J M Roberts
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.

Authors:  Ole J Halvorsen; Svein A Haukaas; Lars A Akslen
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

4.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer.

Authors:  R M Yang; J Naitoh; M Murphy; H J Wang; J Phillipson; J B deKernion; M Loda; R E Reiter
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

5.  Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma.

Authors:  J Tsihlias; L R Kapusta; G DeBoer; I Morava-Protzner; I Zbieranowski; N Bhattacharya; G C Catzavelos; L H Klotz; J M Slingerland
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

6.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.

Authors:  V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

7.  Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.

Authors:  Marija Drobnjak; Jonathan Melamed; Samir Taneja; Kate Melzer; Rosemary Wieczorek; Benjamin Levinson; Anne Zeleniuch-Jacquotte; David Polsky; Jay Ferrara; Roman Perez-Soler; Carlos Cordon-Cardo; Michele Pagano; Iman Osman
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

8.  The impact of Skp2 overexpression on recurrence-free survival following radical prostatectomy.

Authors:  Paul L Nguyen; Douglas I Lin; Junyi Lei; Michelangelo Fiorentino; Elke Mueller; Michael H Weinstein; Michele Pagano; Massimo Loda
Journal:  Urol Oncol       Date:  2009-05-17       Impact factor: 3.498

9.  Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms.

Authors:  Ayman Rahman; Anirban Maitra; Raheela Ashfaq; Charles J Yeo; John L Cameron; Donna E Hansel
Journal:  Am J Clin Pathol       Date:  2003-11       Impact factor: 2.493

10.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

View more
  5 in total

1.  Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.

Authors:  Tsang-Chi Lin; Lung-Hung Tsai; Ming-Chih Chou; Chih-Yi Chen; Huei Lee
Journal:  Tumour Biol       Date:  2015-10-20

Review 2.  Applications of label-free, quantitative phase holographic imaging cytometry to the development of multi-specific nanoscale pharmaceutical formulations.

Authors:  Ed Luther; Livia P Mendes; Jiyai Pan; Daniel F Costa; Vladimir P Torchilin
Journal:  Cytometry A       Date:  2017-03-30       Impact factor: 4.355

3.  Improving prediction of prostate cancer recurrence using chemical imaging.

Authors:  Jin Tae Kwak; André Kajdacsy-Balla; Virgilia Macias; Michael Walsh; Saurabh Sinha; Rohit Bhargava
Journal:  Sci Rep       Date:  2015-03-04       Impact factor: 4.379

4.  Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): potential role as a biomarker in prostate cancer.

Authors:  L Feferman; S Bhattacharyya; R Deaton; P Gann; G Guzman; A Kajdacsy-Balla; J K Tobacman
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-07-09       Impact factor: 5.554

5.  Association of High miR-182 Levels with Low-Risk Prostate Cancer.

Authors:  Bethany Baumann; Andrés M Acosta; Zachary Richards; Ryan Deaton; Anastasiya Sapatynska; Adam Murphy; Andre Kajdacsy-Balla; Peter H Gann; Larisa Nonn
Journal:  Am J Pathol       Date:  2019-01-29       Impact factor: 4.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.